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•»- Introduction
L Agencies responsible for the regulation of civil aviation
are required to contain the risk of crew incapacitation.
Consequently, strategies to identify and exclude pilots
presenting with an excess high risk have been evolved.
Disabling cardiovascular events such as stroke or myo-
y cardial infarction, as well as arrhythmias and sudden car-
diac death, represent the main cardiovascular causes of
T
 sudden inflight incapacity to fly an airplane. The concept
of risk with particular reference to aircrew and the prob-
ability of cardiovascular event has already been discussed
extensively1'"41. It became evident in these analyses that
age and gender represent risk factors of unique import-
*" ance151. Below retirement age, women have a lower risk
of mortality from ischaemic heart disease. Furthermore,
particularly in men, mortality rates from ischaemic heart
disease increase steeply above the age of 45-50. Nothing is
likely to change these two variables, although mortality in
aircrew has been found to be lower than expected from
epidemiological studies in the general population141. These
findings are not altogether surprising, as pilots represent a
*-• selected population characterized by motivation towards
good cardiovascular health.
How does hypertension affect this risk, and what can be
. -i, done about it? There exists overwhelming evidence that
hypertension increases the risk of myocardial infarction
•• and stroke16"81. There is also good evidence that stroke can
be prevented by antihypertensive therapy191. The incidence
of stroke is, however, much less than that of myocardial
, infarction. Therefore, although the prevention of myo-
cardial infarction181 by antihypertensive therapy should
T
 provide a greater benefit, unfortunately, the evidence that
this can be achieved effectively is less convincing. Indeed,
very few controlled prospective antihypertensive inter-
^ vention trials show clear evidence of prevention of myo-
cardial infarction. Only meta-analysis of such studies with
1
 the inherent shortcomings of the technique have been
_, able to provide some evidence suggesting a significant,
albeit much lower than expected decrease in the inci-
» dence of myocardial infarction'9'. It seems thus unlikely
that antihypertensive treatment, per se, can make much
' contribution to the safety of air travel.
The risk of suffering a heart attack even in a European
male is very low below the age of 50151, thus screening
A
 for predictors of such an event can only be useful if such
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variables have a high degree of specificity. Electrocardio-
graphic screening of symptom-free subjects identifies a
very small percentage of pilots at high risk but also misses
others whose risk is not normal for their age. The previous
occurrence of myocardial infarction and/or a history of
angina pectoris does, however, identify subjects at a
markedly higher risk131 who will be excluded from flying a
commercial aircraft.
But pilots with an elevated blood pressure are also
patients. The main goal of therapy thus should be to
reduce the blood pressure and hopefully prolong the life
expectation of the individual pilot, even though this will
have little or no impact on flight safety overall. Of import-
ance, antihypertensive therapy should be appropriate to
the operational environment. No new risk should be
introduced by the therapeutic agent which may poten-
tially hamper the flying capacity of the pilot through such
unwanted effects as orthostatic hypotension, arrhythmia
or sedation.
In the following text, a management strategy is proposed
for aircrew who upon screening exhibit a consistently
elevated blood pressure.
Elevated blood pressure in aircrew
The first requirement is to decide whether a subject has
'true' hypertension, or whether his/her blood pressure is
elevated only during a visit to the doctor—-what com-
monly we term 'white coat' hypertension. There is some
indication, though not conclusive evidence, that the blood
pressure taken in the physician's office is a less good pre-
dictor of risk than the blood pressure measured while the
patient pursues his usual activities1'0"121. Approaches used
to enhance the accuracy of blood pressure evaluation are
self-measurement by the patient, or ambulatory blood
pressure recording, discussed elsewhere in this issue. In
our laboratory, any blood pressure measured outside the
clinic that is on daily average higher than 140/90 mmHg is
considered abnormal and in need of therapeutic care.
When the presence of a high blood pressure is estab-
lished, the usual work-up begins with a full history.
Particular care is taken to identify indicators of cardio-
vascular disease, such as previous events, angina pectoris,
dyspnoea or intermittent claudication1'31. The physical
examination should be conducted according to accepted
practices'141. A search should be made for the presence of
peripheral vascular disease by examination of the optic
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fundus, auscultation for arterial bruits and palpation of
peripheral pulses. The presence or absence of a fourth
heart sound should be noted. The laboratory work-up
should include an electrocardiogram, a blood count and a
complete urine analysis. Measurements should also be
taken of plasma glucose, potassium, creatinine, uric acid,
total cholesterol, HDL cholesterol and triglycerides.
Additional investigations may be justified to character-
ize abnormal findings. These complementary tests may
serve to clear a suspicion of abnormality and in a few they
will confirm the existence of a problem which may be of
concern from the certificatory point of view.
Treatment
NON-PHARMACOLOGICAL THERAPY
The non-pharmacological approach to the treatment of
hypertension has the appeal of introducing few untoward
effects. The efficacy of some of these interventions is, how-
ever, still debated. All such therapies require a continued
effort by the patient, and therefore the critical issue is,
whether long-term blood pressure control can be achieved
and maintained by these means. Most of the trials have
studied the different intervention procedures only over a
relatively short period in order to prove their efficacy.
Over a longer period of time, results are often more dis-
appointing. For this reason, non-pharmacological antihy-
pertensive therapy should probably be regarded in most
cases as a supportive measure rather than an alternative
approach to drug treatment.
WEIGHT REDUCTION
The different non-pharmacological approaches to the
treatment of hypertension in aircrew have been reviewed
previously in some detail'151. Among the dietary measures,
weight reduction by reduction in calorie intake seems
today quite well established as an effective means of
reducing blood pressure. While early uncontrolled studies
demonstrated blood pressure reduction when grossly
overweight patients lost 10 kg or more of weight'16171,
more recent studies have reported blood pressure reduc-
tion with weight loss in the vicinity 4 to 5kg1'8"1. In a
recent study using ambulatory blood pressure monitor-
ing, we found a blood pressure reduction which was
clearly related to the actual weight loss'201. Furthermore,
those patients who lost weight, not only reduced their
blood pressure but also reduced their free cytosolic plate-
let calcium. However, results after 1 to 2 years were dis-
appointing since most of the patients included were back
to their original weight. Thus, even if blood pressure can
be reduced by weight reduction, long-term maintenance
by this therapy seems unreliable12'1.
REDUCTION OF SODIUM INTAKE
Reduction of sodium intake appears rational since
there exists plenty of circumstantial experimental and
clinical evidence to suggest that sodium retention may
play an important role in the pathogenesis of hyperten-
sion'22'. There are also some very well conducted trials
which have demonstrated that blood pressure can be
lowered by a reduction in sodium intake121"251. The prob-
lem is that the impact of moderate salt restriction on
blood pressure is relatively modest. The same can be said
for potassium supplementation'261. Moderate salt restric-
tion tends to enhance the antihypertensive efficacy of
some pharmacological agents and this seems sensible as a
supportive measure in the management of hypertension.
VEGETARIAN DIET
It is likely that vegetarian diets also reduce the ratio of
the dietary sodium/potassium intake. In addition they
decrease the intake of animal lipids. This may explain why,
in a well controlled study, a vegetarian diet was effective in
reducing blood pressure1271. Although of interest from an
investigational standpoint, this observation is clinically
probably not very useful. Calcium supplementation,
advocated by some, has not proven its usefulness in the
treatment of hypertension'281, although the reduction of
consumption or withdrawal is of accepted benefit.
EXERCISE
With regard to life style change, regular exercise can
reduce the blood pressure'291. Notwithstanding, many
patients will not maintain a regular and relatively inten-
sive exercise programme over a period of many years.
Accordingly, there are probably few hypertensive patients
who can be successfully treated for years by regular exer-
cise alone. Biofeedback and relaxation therapy are more
difficult to assess since it is almost impossible to rule out
the placebo effect of the measure.
Taken together, non-pharmacological approaches to
the treatment of hypertension are reasonable, supportive
measures since they represent in general a healthier life
style. While they can be considered risk-free, when applied
excessively they may not be completely harmless. In par-
ticular, low sodium intake in combination with somedrugs
may trigger hypotension and excessive potassium or
calcium supplementation could be ill-advised in patients
with reduced renal function. Furthermore, over-emphasis
of these measures could lead in some patients, who cannot
meet the requirements, to unnecessary feelings of guilt
which may interfere with their quality of life.
PHARMACOLOGICAL THERAPY
There are many different classes of drugs available for
the treatment of hypertension. For all practical purposes,
these drugs can be considered to exhibit similar antihyper-
tensive efficacy, even though this may vary from one class
to another in the individual patient. Accordingly, in this
general discussion concerning the usefulness of different
classes of drug, efficacy is not an issue. Efficacy becomes
important when trying to match the right drug to the right
patient.
One of the main considerations when choosing an anti-
hypertensive drug for a pilot must be attention to the
side-effect profile of the agent used. Side-effects that
are unacceptable include hypotension, arrhythmia,
depression and drowsiness. Consideration also has to be
given to drug interactions, since drug combinations are
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often necessary to normalize blood pressure. These inter-
actions may be detrimental or beneficial; thus side-effects
may only occur when two drugs are administered together
or the side-effects of a certain drug may be attenuated by
the co-administration of a second agent.
There are some other considerations to be made when
administering an antihypertensive drug. Most of the
antihypertensive drugs have been given in the higher rec-
ommended dose, which in some instances has undoubt-
edly led to an unnecessary high incidence of side-effects.
Furthermore, the treating physician has to choose
between a strategy of early combination of two or more
antihypertensive drugs or, alternatively, the sequential
trial of the various classes of antihypertensive drugs.
These concepts have been discussed elsewhere1301.
In the treatment of aircrew, sequential monotherapy
may be preferable to obtain a clear profile of potential
side-effects. Whatever strategies are chosen, monother-
apy or a combination of agents, any drug should be used
whenever possible at the lower limit of the recommended
dosage range.
AGENTS TO AVOID
Before discussing the drugs to be recommended for the
treatment of aircrew, it is useful to identify those drug
classes that should not be used. First, there are the
centrally acting drugs, such as reserpine, clonidine,
guanabenz, guanfacine and methyldopa, and possibly the
lipophilic beta-blocking agents. It is not easy to provide
evidence that task performance may be impaired by these
drugs'31'. Notwithstanding, better agents exist. A second
class of drugs that probably should be avoided includes
the alpha-adrenoceptor blocking agents, such as phenoxy-
benzamine, phentolamine, prazosin, trimazosin, doxa-
zosin, terazosin and urapidil. This group may provoke
some degree of orthostatic hypotension, particularly after
the first dose132'. Some of the newer agents are claimed to
cause little such hypotension, but it appears preferable to
avoid this class of drugs in the treatment of aircrew.
PERMISSIBLE AGENTS
The remaining 'permissible' classes of agents include
the diuretics, the beta-adrenoceptor blocking agents, the
calcium antagonists and the angiotensin II converting
enzyme (ACE) inhibitors, which all can be used as first step
therapy, and the vasodilators, which are recommended
mainly in association with the other drugs.
Diuretics
The diuretic agents represent the longest established
class that is currently still in general use for the treatment of
hypertension. Among the diuretics, hydrochlorothiazide
and the various thiazide derivatives are probably prefer-
able as they induce a smooth and progressive sodium
loss'33'. Side-effects such as potassium loss, hyperuricae-
mia and relative glucose intolerance are all of gradual
onset and are unlikely to cause any sudden in-flight inca-
pacitation. Potassium sparing diuretics such as spirono-
lactone, amiloride and triamterene are equally useful,
be it alone or in combination with thiazide diuretics,
and they provide the advantage of protecting against
hypokalaemia. Doses should not exceed 25 mg od of
hydrochlorothiazide or the equivalent for the thiazide
derivatives or 50-75 mgodspironolactone. Loop diuretics
are rarely necessary, unless there exists some degree of
renal failure and should be avoided altogether in the treat-
ment of aircrew because of the potential risk of excessive
salt deprivation which could lead to hypotension. Urinary
frequency is also likely to be a problem. Diuretics can be
combined with any of the three classes, i.e. beta-blockers,
calcium antagonists and ACE inhibitors, with good addi-
tive antihypertensive efficacy, though the increase in effi-
cacy when combined with calcium antagonists is
debated'341. In combination with ACE inhibitors, diuretic
induced hypokalaemia, hyperuricaemia and possibly also
glucose and lipid alterations may be attentuated'35-361.
Beta blockers
Beta-adrenoceptor blocking agents have been con-
sidered the gold standard for aircrew treatment'371. As
already mentioned on theoretical grounds preference
should be given to compounds with a low lipophilicity,
such as atenolol, nadolol and sotalol'381. It should, how-
ever, not be forgotten that beta-blockers can cause side-
effects such as fatigue, drowsiness, asthma, Raynaud's
phenomenon, and impairment of lower limb circulation.
Beta-blockers may be used with any drug of the three
other classes, though the additive efficacy in combi-
nation with ACE inhibitors may become evident only
in a relatively limited fraction of patients. Beta-blockers
can be safely combined with calcium antagonists of
dihydropyridine type, but association with verapamil
or diltiazem should be avoided because of the risk of
inducing atrio-ventricular block.
Calcium antagonists
The slow channel calcium blocking agents and the ACE
inhibitors represent newer classes of drugs. Because of
lack of long-term experience, they have not been rec-
ommended in the past for treatment of flight crew1371. Even
today, there is still relatively little evidence available
demonstrating the beneficial effects of these compounds
in hypertensive patients, though their antihypertensive
efficacy is well established. By now, both drug classes
have, however, proven to be well tolerated and safe, and
for this reason they should be good candidates for use in
the treatment of hypertensive pilots. In particular, they do
not seem to exhibit significant central effects and they
should not induce orthostatic hypotension.
The calcium antagonists form probably the least hom-
ogenous group since diltiazem and verapamil are quite
different from the dihydropyridine derivatives'391, and
even among the latter there exist considerable differences
in the side-effect profile1401. Side effects such as flushing,
headache and oedema are common but even so, when
used as monotherapy, probably any of the calcium antag-
onists could be considered safe for the treatment of hyper-
tensive pilots. Preference may be given to the longer acting
drugs in order to avoid side-effects such as palpitation
related to rather more abrupt onset of action. Apart from
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verapamil they are probably best combined with a beta-
blocking agent and dihydropyridine derivatives are best
used in this context as already outlined above.
ACE inhibitors
The ACE inhibitors also do not cause orthostatic hypo-
tension in the sodium replete individual, and do not
impair cardiac function'4'1. In combination with diuretic
therapy, they are particularly effective but loop diuretics
should be avoided. Preference here also should be given to
longer acting agents using the lower recommended dose,
e.g. lisinopril or enalapril at a dose of lOmg od or
equivalent. Side-effects such as cough or angioneurotic
oedema should not occur sufficiently suddenly to
incapacitate a pilot during the average duration of a
flight.
The directly acting vasodilators such as hydralazine,
dihydralazine or minoxidil are not recommended as
monotherapy1421. They may, however, be used beneficially
in combination with a beta-blocker or possibly an ACE
inhibitors. Today, most often calcium antagonists have
taken their place. The use of minoxidil in the treatment
of aircrew should be avoided because of the risk of
hypotension.
Conclusions
The four differing classes of antihypertensive drugs, i.e.
the diuretic agents, beta-adrenoceptor blocking agents,
slow channel calcium blockers and ACE inhibitors, pro-
vide a good array of therapeutic tools with which to treat
hypertensive pilots. The use of low doses in monotherapy
as well as in combination is an important feature in any
strategy. Sequential monotherapy, that is a sequential
trial of a representative of each of these four classes, in
the hope of identifying one compound able to control
blood pressure when given alone, is to be recommended.
Combination therapy may be used, if no single agent
provides good blood pressure control. Diltiazem and
verapamil should not be combined with beta-blocking
agents, and loop diuretics should be avoided altogether,
particularly in combination with ACE inhibitors.
Because most pilots belong to an age group which
exhibits a low incidence of sudden incapacitating cardio-
vascular complications due to hypertension, antihyper-
tensive therapy, a priori, has only a small potential to
exert a beneficial effect on air safety. The screening of
aircrew should identify predictors of high risk for an
incapacitating cardiovascular event, including co-existing
lipid disorder, smoking and family history of premature
cardiovascular disease. Antihypertensive strategy in air-
crew is similar to that used for the general population and
the long-term objectives are the same — the maintenance
of optimum long-term health in a pharmacological
environment as free from unwanted effects as possible.
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